DNA RNA and Cells

07 Sep 2016 Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine
07 Sep 2016 Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
07 Sep 2016 Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT
07 Sep 2016 Protocol Submission of OBP-301 (Telomelysin®) for Phase II Clinical Trial in the United States
29 Aug 2016 CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications
24 Aug 2016 Novel Gene Therapy Drug for Huntington's Disease
24 Aug 2016 Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401
22 Aug 2016 The European Commission grants a Conditional Marketing Authorisation to Zalmoxis®, the first immunogene therapy for the treatment of adult patients with high-risk haematological malignancies
19 Aug 2016 Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components
18 Aug 2016 Development of novel Natural Killer (NK) Cell immunotherapeutics pushed by CAR T-cell and gene editing technologies
16 Aug 2016 OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
15 Aug 2016 TCR Target Discovery and Affinity-Optimized TCR T-Cells: high entry barriers favor a small Eurocentric group of technology companies
11 Aug 2016 RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics
10 Aug 2016 Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec
10 Aug 2016 Beyond anti-CD19 CAR T-Cells: the future of CAR T-cells depends on the convergence of technologies
09 Aug 2016 Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
09 Aug 2016 Phase 2 Trial Results of Mesoblast’s Cell Therapy Show Dose-Related Improvements in Biologic Refractory Rheumatoid Arthritis
08 Aug 2016 Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)
05 Aug 2016 Bellicum Announces BPX-501 European Regulatory Updates
04 Aug 2016 First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation
04 Aug 2016 Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
03 Aug 2016 AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
02 Aug 2016 Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals
02 Aug 2016 Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
01 Aug 2016 Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing